Definitive Agreement to Acquire Exelead will Strengthen MilliporeSigma’s CDMO Offering for mRNA
News Release
- Targeted acquisition to accelerate novel modalities service offering
- Exelead, a full-service CDMO, focusing on Lipid Nanoparticle formulations enhances the mRNA and lipid manufacturing capabilities of MilliporeSigma
- Customers will benefit from unique and integrated solutions across the mRNA value chain
Burlington, MA, January 6, 2022 – MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced the signing of a definitive agreement to acquire Exelead, a biopharmaceutical contract development and manufacturing organization (CDMO) for approximately USD 780 million in cash. Exelead specializes in complex injectable formulations, including Lipid Nanoparticle (LNP) based drug delivery technology which is key in mRNA therapeutics for use in Covid-19 and many other indications.
“Novel modalities, particularly mRNA, present a highly attractive business opportunity as pharma and biotech pipelines are increasingly building on them beyond Covid-19. The acquisition of Exelead will further enable our company to capture the significant potential of the fast-growing market for mRNA therapies by providing leading CDMO services to our customers,” explained Belén Garijo, Chair of the Executive Board and CEO of Merck KGaA, Darmstadt Germany.
“Exelead’s capabilities and expertise will strengthen our CDMO mRNA offering. We are excited to work with Exelead’s experienced team. Together, we will provide our customers with a unique and truly integrated offering across the mRNA manufacturing process. This will significantly decrease supply chain complexity and enhance speed-to-market to ultimately accelerate access to life-enhancing therapeutics for patients worldwide,” added Matthias Heinzel, Member of the Executive Board of Merck KGaA, Darmstadt, Germany and CEO Life Science.
“With the Life Science business sector’s long-established expertise in the biopharmaceutical industry, Exelead will now be in a greater position to serve the needs of customers and patients. The business combination will further strengthen our renowned technological know-how and unique expertise that we bring to the CDMO space,” said John Rigg, Chief Executive Officer of Exelead.
The acquisition of Exelead is another milestone to accelerate innovation in the Process Solutions business unit, one of Merck KGaA, Darmstadt, Germany’s three growth engines (Big 3), through targeted smaller to medium-sized acquisitions with high impact. It follows the company’s acquisition of AmpTec, a leading Hamburg, Germany-based, mRNA CDMO, announced at the beginning of 2021. The transaction enhances the company’s more than 20 years' experience in producing lipids, one of the critical components for the formulation of mRNA therapeutics including Covid-19 vaccines as well as its mRNA manufacturing capabilities.
Exelead has more than ten years of experience in all development phases from pre-clinical development to commercial contract manufacturing for LNP formulations, including fill and finish. Exelead is headquartered in Indianapolis, Indiana, United States, where it operates its production and employs more than 200 experts. Merck KGaA, Darmstadt, Germany intends to continue to invest in mRNA as a modality and will scale up this technology at Exelead’s existing site in Indianapolis.
The transaction is expected to close in the first quarter of 2022 and is subject to regulatory clearances as well as the satisfaction of other customary closing conditions.
About the Life Science business of Merck KGaA, Darmstadt, Germany
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has more than 23,000 employees and 59 manufacturing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services. Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics.
Around 58,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2020, Merck KGaA, Darmstadt, Germany generated sales of € 17.5 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck KGaA, Darmstadt, Germany, visit www.emdgroup.com.
All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
Follow MilliporeSigma on Twitter @MilliporeSigma, on Facebook @MilliporeSigma and on LinkedIn.
Para seguir leyendo, inicie sesión o cree una cuenta.
¿No tiene una cuenta?